Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

33 results about "Advanced ovarian cancer" patented technology

Advanced ovarian cancer means that the cancer has spread outside the ovary. It may have spread within the pelvis or abdomen, or further away to other parts of the body such as the lungs.

Detection of cancer by elevated levels of BCL-2

ActiveUS20080009005A1Lower Level RequirementsSimple and rapid and reliable and accurate and cost-effectiveBioreactor/fermenter combinationsBiological substance pretreatmentsOncologyCancer research
The present invention relates to a method for the diagnosis, prognosis, and monitoring of cancer, such as early or late stage ovarian cancer, in a subject by detecting Bcl-2 in a biological sample from the subject, preferably a urine or blood sample. Bcl-2 may be measured using an agent that detects or binds to Bcl-2 protein or an agent that detects or binds to encoding nucleic acids, such as antibodies specifically reactive with Bcl-2 protein or a portion thereof. The invention further relates to kits for carrying out the methods of the invention. The invention further relates to a device for the rapid detection of Bcl-2 in a bodily fluid and methods for rapidly measuring Bcl-2 in a bodily fluid.
Owner:UNIV OF SOUTH FLORIDA

Traditional Chinese medicine compound preparation for treating ovarian cancer and preparation method of traditional Chinese medicine compound preparation

The invention belongs to the field of traditional Chinese medicine and relates to a traditional Chinese medicine compound preparation for treating ovarian cancer and a preparation method of the traditional Chinese medicine compound preparation. According to the traditional Chinese medicine compound preparation, extracts of bulk medicine such as astragalus mongholicus, codonopsis pilosula, rehmannia root, sculellaria barbata, asparagus cochinchinensis, medlar, cornu cervi, fiveleaf akebia fruit, elecampane and radix paeoniae alba are prepared into solid and liquid preparations. Animal experiment results show that the weight loss and the white cell reduction can be relieved, the T lymphocyte function is improved, the bax expression is increased, the cancer cell apoptosis is promoted, the anti-tumor angiogenesis effect is realized, the oxygen deficiency microenvironment of tumor cells is improved, and the sensitivity of ovarian cancer cells on chemotherapeutics is enhanced. Clinical test results show that the clinical symptoms of later-stage ovarian cancer patients can be relieved, and the survival quality of patients is improved; the chemotherapy toxic and side effect is lightened, and the chemotherapy tolerance and the compliance of the patients are improved; and the uncontrolled and recurrence rate of later-stage ovarian cancer can be reduced, and the five-year survival rate is improved; and no obvious adverse reaction exists, and good safety is realized. The traditional Chinese medicine compound preparation is applicable to the treatment on ovarian cancer and ovarian cancer postoperative chemotherapy patients.
Owner:SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M

System for predicting prognosis of locally advanced gastric cancer

The present invention relates to a novel system for predicting a prognosis capable of predicting the prognosis of locally advanced gastric cancer, and more specifically, capable of predicting a clinical result after a resection during gastric cancer surgery through gene set enrichment comparative analysis.
Owner:NOVOMICS CO LTD

Method for detecting ER gene of peripheral blood circulating tumor cells of patient suffering from advanced breast cancer

The invention discloses a method for detecting an ER gene of peripheral blood circulating tumor cells of a patient suffering from advanced breast cancer. The method comprises the steps of conducting separation with a membrane filtration device, so that CTC in peripheral blood of the patient suffering from advanced breast cancer is obtained; identifying the peripheral blood circulating tumor cells of the patient suffering from advanced breast cancer through the cellular immunofluorescence technique; preparing thin layer sections through the cell paraffin block technique; further detecting the ER expression condition of the peripheral blood circulating tumor cells of the patient suffering from advanced breast cancer through the immunohistochemical technique. According to the method, CTCs are separated and enriched by means of the ISET technique, and the CTCs are identified through the cellular immunofluorescence technique, so that the difficulty existing in CTCs identification conducted through the pure ISET technique and false negativeness existing in CTCs identification conducted through the pure immunological detection technique are overcome. The technique is not high in equipment requirement, the method is easy to grasp, and real-time monitoring can be conducted. By means of the technical method, the ER expression condition of the patient suffering from advanced breast cancer can be detected without picking breast cancer tissues.
Owner:山东发现生物技术有限公司

Galectin-3 to Treat Ovarian Cancer

InactiveUS20150157691A1Reduce eliminateReduce or eliminate the ovarian cancerCompound screeningOrganic active ingredientsGynecologyMotility
The present invention includes a method for the treatment of an advanced ovarian cancer, comprising: identifying a patient with advanced ovarian cancer; and administering to the patient an effective amount of truncated, dominant negative form of Galectin-3 sufficient to reduce the advanced ovarian cancer. In certain aspects, the truncated, dominant negative form of Galectin-3 is provided in an amount sufficient to reduce at least one of growth, motility, invasion, angiogenesis, or prevents Akt / NF-κB activation of the ovarian cancer.
Owner:TEXAS TECH UNIV SYST

Administration of Karenitecin for the Treatment of Platinum and/or Taxane Chemotherapy-Resistant or -Refractory Advanced Ovarian Cancer

The present invention discloses and claims methods and compositions for the treatment of subjects having advanced ovarian cancer, including platinum and / or taxane chemotherapy resistant or refractory sub-populations, with the administration to the subject having advanced ovarian cancer of the silicon-containing highly lipophilic camptothecin derivative (HLCD), Karenitecin (also known as BNP1350; cositecan; 7-[(2′-trimethylsilyl)ethyl]-20(S) camptothecin) in an amount sufficient to provide a therapeutic benefit. The administration of Karenitecin by intravenous (i.v.) and / or oral methodologies are also disclosed and claimed. Methods for the administration of Karenitecin to increase Progression Free Survival (PFS) are also disclosed and claimed herein.
Owner:CROWN BIOSCIENCE INC

Traditional Chinese medicine preparation for treating advanced breast cancer by virtue of combined chemotherapy

The invention belongs to the technical field of medicines, and particularly relates to a traditional Chinese medicine preparation for treating advanced breast cancer by virtue of combined chemotherapy and a preparation method of the traditional Chinese medicine preparation. The preparation is prepared from the following medicinal materials: rhizoma cyperi, fingered citron, radix pseudostellariae, deer-horn glue, placenta hominis, spatholobus suberctu, fritillary bulb, pinellia ternata, indigo naturalis and licorice root. The traditional Chinese medicine preparation has the advantages of simple prescription, exquisite drug usage and reasonable compatibility, has magical effects of soothing liver, strengthening spleen, promoting qi circulation, relieving depression, promoting blood circulation to remove stasis, clearing heat and eliminating stagnation, has an extremely targeted curative effect on combined chemotherapy of advanced breast cancer, can be used for remarkably reducing toxic or side effects generated by chemotherapy, has a remarkable curative effect for improving physical strength and immunity, and is an effective medicine for treating advanced breast cancer by virtue of combined chemotherapy.
Owner:QINGDAO MERRITT MEDICAL TECH CO LTD

Biflavonoid compound and application thereof

ActiveCN108586410AAdd new usesStrong PARP-1 inhibitionHeavy metal active ingredientsOrganic active ingredientsBiflavonoidGene defect
The invention discloses a biflavonoid compound and application thereof, belongs to the field of natural pharmaceutical chemistry and pharmacotherapy, and particularly relates to a C-3'-C-8''-type biflavonoid compound or pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound, medical application thereof, particularly application thereof as a chemotherapeuticplatinum medicine sensitizer, and a therapeutic effect on BRCA gene defect-type advanced ovarian cancer.
Owner:CHINA PHARM UNIV

Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types

The present invention discloses and claims methods and compositions for the treatment of platinum and / or taxane cancer treating agent-resistant / -refractory sub-populations and / or the mucinous adenocarcinoma sub-type of ovarian cancer subjects with the silicon-containing highly lipophilic camptothecin derivative (HLCD), Karenitecin (also known as BNP1350; cositecan; 7-[(2′-trimethylsilyl)ethyl]-20(S) camptothecin). The administration of Karenitecin by intravenous (i.v.) and / or oral methodologies are also disclosed and claimed. Karenitecin analogues, including but not limited to, Germanium-substituted Karenitecin, Deuterated Karenitecin, and “flipped” E-ring Karenitecin, are disclosed and claimed. In addition, Karenitecin and one or more cancer treating agents administered either concomitantly or in series via oral and / or i.v. means, are also disclosed and claimed. Methods for the administration of Karenitecin to: (i) increase Progression Free Survival (PFS); (ii) increase the platinum-free time interval; (iii) decrease CA-125 marker levels; and (iv) mitigate or prevent chemotherapeutic drug-resistance from developing are disclosed and claimed herein. Methods for the use of Karenitecin to treat advanced solid tumors; refractory or recurrent solid tumors; recurrent malignant glioma; primary malignant glioma; persistent or recurrent epithelial ovarian or primary peritoneal carcinoma; and other identified cancer types are also disclosed and claimed.
Owner:CROWN BIOSCIENCE INC

A traditional Chinese medicine composition used for treating ovarian cancer

The invention discloses a traditional Chinese medicine composition used for treating ovarian cancer. The composition comprises, by weight: 30-40 parts of hedyotis, 20-30 parts of frankincense, 15-20 parts of oriental waterplantain rhizome, 20-30 parts of Sichuan lovage rhizome, 20-30 parts of lightyellow sophora roots, 15-20 parts of debark peony root, 15-20 parts of brown sugar, 30-40 parts of Cortex Cinnamomi, 30-40 parts of liquorice roots, 30-40 parts of Herba Leonuri, and 15-20 parts of woolly grape fern. The composition is capable of suppressing tumor cells, reinforcing the vital essenceand strengthening the primordial qi, boosting immunity of patients, reducing pain of patients, improving life quality of patients and prolonging survival time of patients, and is low in side effect,simple to prepare and convenient to take. Raw materials are easily available, the price is low, and the traditional Chinese medicine composition is suitable for long-term taking of patients. Patientswith advanced ovarian cancer who have relapsed after postoperation chemotherapy, or who cannot tolerate chemotherapy, or who lose the chance of surgery, or who cannot tolerate surgery due to poor physical condition, can be treated by adopting the traditional Chinese medicine composition.
Owner:山东大学深圳研究院

Application of RBM10 gene

The invention relates to application of an RBM10 gene. The invention discloses a biomarker for evaluating the curative effect of Chiauranib or guiding the medication of Chiauranib or predicting the treatment effect of ovarian cancer. The biomarker is an RBM10 gene or mRNA thereof or a protein or a protein fragment coded by the RBM10 gene. According to the application, the progression-free survival (PFS) of a patient is taken as a curative effect index, the relevance between RBM10 gene variation and the curative effect of Chiauranib is verified, the detection of RBM10 gene mutation information can guide the clinical medication of Chiauranib and evaluate the curative effect of Chiauranib on tumor treatment, and Chiauranib is particularly suitable for recurrent and advanced ovarian cancer.
Owner:SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD +1

Administration of karenitecin for the treatment of platinum and/or taxane chemotherapy-resistant or -refractory advanced ovarian cancer

The present invention discloses and claims methods and compositions for the treatment of subjects having advanced ovarian cancer, including platinum and / or taxane chemotherapy resistant or refractory sub-populations, with the administration to the subject having advanced ovarian cancer of the silicon-containing highly lipophilic camptothecin derivative (HLCD), Karenitecin (also known as BNP1350; cositecan; 7-[(2′-trimethylsilyl)ethyl]-20(S) camptothecin) in an amount sufficient to provide a therapeutic benefit. The administration of Karenitecin by intravenous (i.v.) and / or oral methodologies are also disclosed and claimed. Methods for the administration of Karenitecin to increase Progression Free Survival (PFS) are also disclosed and claimed herein.
Owner:CROWN BIOSCIENCE INC

Use of cedar acid in reversing paclitaxel medical resistance in ovarian cancer

The invention discloses a use of cedar acid in reversing paclitaxel medical resistance in ovarian cancer. Ovarian cancer is one of the three major malignant tumors of female reproductive system, and the survival time of most patients with advanced ovarian cancer is less than 5 years. Clinical treatment of ovarian cancer usually uses cytoreductive surgery and postoperative chemotherapy with platinum and paclitaxel. However, ovarian cancer cell resistance to chemotherapy drugs leads to high recurrence rate and mortality, so it becomes the bottleneck of clinical treatment. The invention disclosesthat yew antler acid, yew antler alkyd and cedric acid can enhance the proliferation inhibition effect of Taxol on A2780 / Taxol cells in different degrees, improve the sensitivity of cells to Taxol, and can be developed as a medicine for reversing the resistance of ovarian cancer to taxol. The use is characterized in that the yew antler acid, yew antler alkyd and cedric acid can enhance the proliferation inhibition effect of Taxol on A2780 / Taxol cells in different degrees and improve the sensitivity of cells to Taxol.
Owner:QINGDAO CENT HOSPITAL

Internal and external drainage tube for advanced liver cancer

ActiveCN107929915AImproved liver functionProlong lifeCatheterGynecologyDrainage catheters
The invention relates to an internal and external drainage tube for advanced liver cancer. The internal and external drainage tube comprises a COOK drainage catheter body (1) and is characterized in that the COOK drainage catheter body (1) comprises a bile-duct drainage part (2) extending into the bile duct during use, a liver drainage part (3) located in the liver during use and an in-vitro outerpart (4). The internal and external drainage tube has the advantages that the double drainage manner sequentially performing internal drainage and external drainage is adopted, safety can be guaranteed to the maximum extent, the external drainage can be used even if the internal drainage is forced to stop, and external drainage time is reduced; meanwhile, an self-overflow guide device is used, drainage failure caused by the fact the excessive effusion cannot be discharged when the internal drainage is forced to stop and the external drainage is not started, and problems in the prior art are well solved.
Owner:GENERAL HOSPITAL OF THE NORTHERN WAR ZONE OF THE CHINESE PEOPLES LIBERATION ARMY

A traditional Chinese medicine preparation used for treating ovarian cancer

The invention provides a traditional Chinese medicine preparation used for treating ovarian cancer. The traditional Chinese medicine preparation is prepared from the following bulk drugs, by weight: 8-10 parts of nux vomica, 10-15 parts of Herba Patriniae, 10-20 parts of hedyotis, 12-16 parts of Rhizoma Drynariae, 14-20 parts of Caulis Spatholobi, 20-25 parts of Sagina japonica, 15-20 parts of Cortex Cinnamomi, 20-25 parts of Sichuan lovage rhizome, 20-30 parts of Semen Persicae, 10- 15 parts of Rhizoma Zingiberis, 30-40 parts of liquorice roots, and 30-40 parts of Fructus Crataegi. The preparation is capable of suppressing tumor cells, reinforcing the vital essence and strengthening the primordial qi, boosting immunity of patients, reducing pain of patients, improving life quality of patients and prolonging survival time of patients, and is low in side effect, simple to prepare and convenient to take. Raw materials are easily available, the price is low, and the traditional Chinese medicine preparation is suitable for long-term taking of patients. Patients with advanced ovarian cancer who have relapsed after postoperation chemotherapy, or who cannot tolerate chemotherapy, or who lose the chance of surgery, or who cannot tolerate surgery due to poor physical condition, can be treated by adopting the traditional Chinese medicine preparation.
Owner:SHANDONG UNIV QILU HOSPITAL

Injection for treating advanced ovarian cancer and preparation method thereof

The invention belongs to the technical field of medicines, in particular to an injection for treating advanced ovarian cancer and a preparation method thereof.The injection is mainly prepared from the active ingredients including carboplatin, twain-20, ammonia water, a pH regulator and water for injection.The injection is stable in quality and simple in process, an impurity 1,1-cyclobutane dicarboxylic acid and other impurities do not change obviously, and the safety of the injection in clinical use is improved.
Owner:周英杰

Establishment and improvement of advanced ovarian cancer satisfactory tumor cell deduction preoperative evaluation and prediction model

The invention relates to establishment and improvement of a preoperative evaluation and prediction model for satisfactory tumor cell deduction of advanced ovarian cancer. Herein, improved modeling is carried out on the basis of the Sduidan score table; and serological HE4 and ROMA indexes are added, the HE4 calculated according to the data is larger than 264.7 pmol/L, the CA125 calculated according to the data is larger than 545.6 U/ml, the ROMA indexes calculated according to the data are larger than 90.0%, and the prediction scores are given to be one score respectively; and then two different radiology department high-age doctors perform secondary radiology reading scoring to calculate predicted scores of all cases; and finally, an ROC curve is drawn according to a prediction score and an operation result to obtain an area AUC under a subject working curve, and evaluation of the model is carried out to predict the clinical value of the unsatisfactory tumor cell deduction operation of the advanced ovarian cancer patient. The prediction value of the prediction model is higher than that of a Suidan prediction model. When the model is used for predicting the dissatisfactory tumor cell deficit operation, the sensitivity is obviously higher than that of a Suidan score table, which provides a basis with a certain prediction value for clinicians to judge whether the dissatisfactory tumor cell deficit operation can be performed or not.
Owner:GENERAL HOSPITAL OF NINGXIA MEDICAL UNIV

A kind of traditional Chinese medicine compound preparation for treating ovarian cancer and its preparation method

The invention belongs to the field of traditional Chinese medicine and relates to a traditional Chinese medicine compound preparation for treating ovarian cancer and a preparation method of the traditional Chinese medicine compound preparation. According to the traditional Chinese medicine compound preparation, extracts of bulk medicine such as astragalus mongholicus, codonopsis pilosula, rehmannia root, sculellaria barbata, asparagus cochinchinensis, medlar, cornu cervi, fiveleaf akebia fruit, elecampane and radix paeoniae alba are prepared into solid and liquid preparations. Animal experiment results show that the weight loss and the white cell reduction can be relieved, the T lymphocyte function is improved, the bax expression is increased, the cancer cell apoptosis is promoted, the anti-tumor angiogenesis effect is realized, the oxygen deficiency microenvironment of tumor cells is improved, and the sensitivity of ovarian cancer cells on chemotherapeutics is enhanced. Clinical test results show that the clinical symptoms of later-stage ovarian cancer patients can be relieved, and the survival quality of patients is improved; the chemotherapy toxic and side effect is lightened, and the chemotherapy tolerance and the compliance of the patients are improved; and the uncontrolled and recurrence rate of later-stage ovarian cancer can be reduced, and the five-year survival rate is improved; and no obvious adverse reaction exists, and good safety is realized. The traditional Chinese medicine compound preparation is applicable to the treatment on ovarian cancer and ovarian cancer postoperative chemotherapy patients.
Owner:SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M

A use of shikonian acid for reversing drug resistance of ovarian cancer to paclitaxel

The invention discloses use of lacca acid in reversing paclitaxel medical resistance in ovarian cancer. Ovarian cancer is one of the three major malignant tumors of female reproductive system, and thesurvival time of most patients with advanced ovarian cancer is less than 5 years. Clinical treatment of ovarian cancer usually uses cytoreductive surgery and postoperative chemotherapy with platinumand paclitaxel. However, ovarian cancer cell resistance to chemotherapy drugs leads to high recurrence rate and mortality, so it becomes the bottleneck of clinical treatment. The invention discloses that lacca acid, lacca acid alkyd and cedric acid can enhance the proliferation inhibition effect of Taxol on A2780 / Taxol cells in different degrees, improve the sensitivity of cells to Taxol, and canbe developed as a medicine for reversing the resistance of ovarian cancer to taxol. The invention is characterized in that the lacca acid, lacca acid alkyd and cedric acid can enhance the proliferation inhibition effect of Taxol on A2780 / Taxol cells in different degrees and improve the sensitivity of cells to Taxol.
Owner:菅金波

Use of yew antler alkyd for reversing ovarian cancer resistance to paclitaxel

The invention discloses a use of yew antler alkyd for reversing ovarian cancer resistance to paclitaxel. Ovarian cancer is one of the three major malignant tumors of female reproductive system, and the survival time of most patients with advanced ovarian cancer is less than 5 years. Clinical treatment of ovarian cancer usually uses cytoreductive surgery and follows by postoperative chemotherapy with platinum and paclitaxel. However, ovarian cancer cell resistance to chemotherapy drugs leads to high recurrence rate and mortality, so it becomes the bottleneck of clinical treatment. The inventiondiscloses that yew antler acid, yew antler alkyd and cedric acid can enhance the proliferation inhibition effect of Taxol on A2780 / Taxol cells in different degrees, improve the sensitivity of cells to Taxol, and can be developed as a medicine for reversing the resistance of ovarian cancer to taxol.
Owner:普瑞赛森(山东)生物医学科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products